Results 191 to 200 of about 467,609 (357)

[Performing integrative transcriptomic and chemical screening to identify patient-specific vulnerabilities in poor-prognosis acute myeloid leukemia].

, 2021
Mari Hashimoto, Fumihiko Ishikawa
openalex   +2 more sources

Nanogel‐Mediated Immunotherapy to Tackle Cancer and Inflammatory Diseases

ChemistryEurope, EarlyView.
Nanogels formed through self‐assembly, microemulsion, or precipitation polymerization method enable precise delivery of immunotherapeutic factors and immune cell targeting, thus effectively modulating immune responses. This review highlights recent advances in stimuli‐responsive nanogel design, underlying mechanisms, and their potentials to tackle ...
Ziwen Zhang, Jinxia Wang, Guang‐Zhi Jin, István Bányai, Dzmitry Shcharbin, Ivan Stoikov, Mingwu Shen, Xiangyang Shi   +7 more
wiley   +1 more source

Precision medicine with car cells in acute myeloid leukemia: where are we? [PDF]

Front Immunol
Zanetti LC, Tomaz V, de Souza IF, Campregher PV, Hamerschlak N, Kerbauy LN.   +5 more
europepmc   +1 more source

Induction of apoptosis and differentiation by Na/H exchanger 1 modulation in acute myeloid leukemia cells

, 2019
Shin Young Hyun, Eun Jung Na, Ji Eun Jang, Haerim Chung, Soo‐Jeong Kim, Jin Seok Kim, Jee Hyun Kong, Kwang Yong Shim, Jong In Lee, Yoo Hong Min, June‐Won Cheong   +10 more
openalex   +2 more sources

Philadelphia-positive chronic myeloid leukemia with a chromosome 22 breakpoint outside the breakpoint cluster region [published erratum appears in Blood 1988 Jan;71(1):272] [PDF]

, 1987
Licia Selleri, Franco Narni, Giovanni Emilia, A Colò, Patrizia Zucchini, Donatella Venturelli, Amedea Donelli, U Torelli, Giuseppe Torelli   +8 more
openalex   +1 more source

Monosomal karyotype as an adverse risk factor for inferior survivals in children with acute myeloid leukemia

, 2021
Xingjuan Wang, Xi Chen, Hu Dou, Zhenzhen Yang, Junqin Bi, Yi Huang, Fu Guo, Yuan Lan, Ling Lu, Jie Yu, Liming Bao   +10 more
openalex   +1 more source

Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Asciminib is the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP) in patients with chronic myeloid leukemia. This phase 1, two‐treatment‐period, drug‐drug interaction study evaluated the effect of steady‐state asciminib on the pharmacokinetics of atorvastatin.
Matthias Hoch, Wendy Weis, Felix Huth, Seshulatha Jamalapuram, Michelle Quinlan, Amarnath Bandaru, Suleyman Eralp Bellibas, Asmae Mirkou, Shruti Kapoor, Shefali Kakar   +9 more
wiley   +1 more source

Prospective validation of podoplanin expression as a diagnostic biomarker of acute promyelocytic leukemia

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Acute promyelocytic leukemia (APL) is a medical emergency that needs immediate diagnosis and treatment. Podoplanin, a transmembrane glycoprotein that binds CLEC‐2 on platelets, was recently demonstrated to be abnormally expressed in leukemic blasts in APL, as opposed to other forms of AML, in a study using thawed primary cells.
Camilla Maria de Alencar Saraiva, Carla Roberta Peachazepi Moraes, Bruno Kosa Lino Duarte, Gislaine Borba Oliveira, Herton Luiz Alves Sales Filho, Paula de Melo Campos, Sara Teresinha Olalla Saad, Erich Vinicius De Paula   +7 more
wiley   +1 more source

Dysregulation of HOXA genes in acute myeloid leukemia and targeted therapy. [PDF]

NPJ Precis Oncol
Huang W, Zhang F, Zhang Z, Wang Q, Chen S.   +4 more
europepmc   +1 more source

Acute myeloid leukemia

HemaSphere, 2019
openaire   +3 more sources